- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Waltham Today
By the People, for the People
GLP-1 Developer Kailera, Proteomics Firm Alamar File for IPO
Kailera Therapeutics and Alamar Biosciences seek to go public on U.S. exchanges
Mar. 28, 2026 at 1:50pm
Got story updates? Submit your updates here. ›
Kailera Therapeutics, a weight loss drug developer with four GLP-1 candidates in the pipeline, and Alamar Biosciences, a commercial-stage proteomics company, have both filed for initial public offerings with the SEC. The companies are based in Waltham, Massachusetts and are looking to raise funds through their U.S. IPOs.
Why it matters
The filings from Kailera and Alamar reflect ongoing activity in the biotech and life sciences sectors, with companies seeking to tap public markets for growth capital. GLP-1 drugs have become an increasingly important treatment for obesity and type 2 diabetes, while proteomics is an emerging field with applications in drug discovery and diagnostics.
The details
Kailera Therapeutics, founded in 2018, is developing a pipeline of glucagon-like peptide-1 (GLP-1) receptor agonist drugs for weight loss and related conditions. Alamar Biosciences, founded in 2016, is a commercial-stage proteomics company that provides protein analysis services and is developing its own diagnostic tests.
- Kailera Therapeutics and Alamar Biosciences filed for their respective IPOs with the SEC on Friday, March 28, 2026.
The players
Kailera Therapeutics
A weight loss drug developer based in Waltham, Massachusetts that has four GLP-1 candidates in its pipeline.
Alamar Biosciences
A commercial-stage proteomics company based in Waltham, Massachusetts that provides protein analysis services and is developing diagnostic tests.
The takeaway
The IPO filings from Kailera and Alamar highlight the ongoing investor interest in biotech and life sciences companies, particularly those focused on emerging areas like GLP-1 drugs and proteomics. The funds raised could help these Massachusetts-based firms accelerate their drug development and commercialization efforts.
